Royalty Pharma plc Class A Ordinary Shares

RPRX trades at a striking 37x earnings while sitting at its 52-week peak, a combination that suggests complacency in a sector typically valued much cheaper. The RSI of 58.5 indicates neither overbought nor oversold conditions—plenty of room to run higher, yet no imminent correction signals. With minimal short interest at 2.74% of float, there's negligible squeeze dynamics, but the absence of skeptical positioning means limited downside cushioning if sentiment shifts. For a pharmaceutical royalty company, the valuation premium relative to historical pharma multiples warrants scrutiny, especially at cycle highs where mean reversion risk tends to materialize.